PCIDB

KNApSAcK Metabolite C00047828

Metabolite

KNApSAcK Entry

id C00047828
Name Cycloheximide
CAS RN 66-81-9
Standard InChI InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1
Standard InChI (Main Layer) InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)

Cluster

Phytochemical cluster
KCF-S cluster No. 2705

Link

ChEMBL

By standard InChI CHEMBL123292
By standard InChI Main Layer CHEMBL123292 CHEMBL356004 CHEMBL225699 CHEMBL600517 CHEMBL582062 CHEMBL1078564 CHEMBL1358722 CHEMBL1552697

KEGG

By LinkDB C06685

CTD

By CAS RN D003513

Species

Summary

Plant class

class name count

Family

family name count
Streptomycetaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Streptomyces sp. H7667 550813 Streptomycetaceae Bacteria

Human Protein / Gene in interaction

131 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL123292 CHEMBL1078564 CHEMBL1358722 CHEMBL1741321 (2) CHEMBL1909136 (2)
1 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL123292 CHEMBL1613992 (1) CHEMBL1738132 (1)
7 / 44
Q16637 Survival motor neuron protein Unclassified protein CHEMBL123292 CHEMBL356004 CHEMBL1358722 CHEMBL1552697 CHEMBL1613842 (5)
4 / 2
P17861 X-box-binding protein 1 Unclassified protein CHEMBL1358722 CHEMBL1738682 (1)
1 / 0
Q9UIF8 Bromodomain adjacent to zinc finger domain protein 2B Unclassified protein CHEMBL1358722 CHEMBL1738312 (1)
0 / 0
Q99700 Ataxin-2 Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL2114784 (3)
1 / 1
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL123292 CHEMBL1909139 (2)
0 / 0
P27338 Amine oxidase [flavin-containing] B Oxidoreductase CHEMBL123292 CHEMBL965567 (1)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL123292 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL123292 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL123292 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL123292 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL123292 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL123292 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL123292 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL123292 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL123292 CHEMBL1909199 (2)
0 / 0
Q03181 Peroxisome proliferator-activated receptor delta NR1C2 CHEMBL123292 CHEMBL1794524 (3)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL123292 CHEMBL1909197 (2)
2 / 2
Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Enzyme CHEMBL123292 CHEMBL759110 (1)
0 / 0
P02545 Prelamin-A/C Unclassified protein CHEMBL1358722 CHEMBL1552697 CHEMBL1614544 (1) CHEMBL1614073 (1)
11 / 10
P37840 Alpha-synuclein Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL2354282 (2)
4 / 2
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL123292 CHEMBL1794561 (1)
3 / 1
P19793 Retinoic acid receptor RXR-alpha NR2B1 CHEMBL123292 CHEMBL1794371 (1) CHEMBL1794471 (3)
0 / 0
P00918 Carbonic anhydrase 2 Lyase CHEMBL123292 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL123292 CHEMBL965566 (1) CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL123292 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL123292 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL123292 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL123292 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909093 (2)
0 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL123292 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL123292 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL123292 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL123292 CHEMBL1078564 CHEMBL1358722 CHEMBL1741325 (2) CHEMBL1909135 (2)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL123292 CHEMBL1909203 (2)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL123292 CHEMBL1794376 (2)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL123292 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL123292 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL123292 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL123292 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL123292 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL123292 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL123292 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL123292 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL123292 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL123292 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL123292 CHEMBL1358722 CHEMBL1614458 (2)
0 / 0
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 Enzyme CHEMBL123292 CHEMBL682338 (1)
0 / 0
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 Enzyme CHEMBL123292 CHEMBL682336 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL123292 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL123292 CHEMBL1358722 CHEMBL999906 (1) CHEMBL999907 (1)
CHEMBL999922 (1) CHEMBL999923 (1)
CHEMBL1614456 (1) CHEMBL1613803 (1)
0 / 0
P42858 Huntingtin Unclassified protein CHEMBL1358722 CHEMBL1613918 (1)
1 / 1
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL1794584 (2)
2 / 0
O75496 Geminin Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL2114843 (2) CHEMBL2114780 (1)
0 / 0
P51151 Ras-related protein Rab-9A Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL1613838 (2)
0 / 0
P13639 Elongation factor 2 Unclassified protein CHEMBL123292 CHEMBL1228366 (1) CHEMBL1228367 (1)
CHEMBL1228368 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL123292 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL123292 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL123292 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL123292 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL123292 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL123292 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL123292 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL123292 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL123292 CHEMBL1909100 (2)
0 / 0
P10145 Interleukin-8 Secreted protein CHEMBL123292 CHEMBL2114835 (1)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL123292 CHEMBL1909167 (2)
1 / 0
Q9Y237 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 Enzyme CHEMBL123292 CHEMBL759483 (1)
0 / 0
P49841 Glycogen synthase kinase-3 beta Gsk CHEMBL123292 CHEMBL1078564 CHEMBL1113068 (2) CHEMBL1113069 (2)
CHEMBL1113070 (2) CHEMBL1113071 (2)
CHEMBL1113072 (2) CHEMBL1113073 (2)
CHEMBL1113074 (2) CHEMBL1113075 (2)
0 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL123292 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL123292 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL123292 CHEMBL1909110 (2)
1 / 0
P43220 Glucagon-like peptide 1 receptor Glucagon-like peptide receptor CHEMBL123292 CHEMBL1358722 CHEMBL2114788 (2)
0 / 0
Q9NWM8 Peptidyl-prolyl cis-trans isomerase FKBP14 Enzyme CHEMBL123292 CHEMBL682335 (1)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL123292 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL123292 CHEMBL1909119 (2)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL123292 CHEMBL1794401 (1)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL123292 CHEMBL1794382 (3) CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL123292 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL123292 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL123292 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL123292 CHEMBL1909109 (2)
2 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL123292 CHEMBL1794293 (1) CHEMBL1794510 (2)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL123292 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL123292 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL123292 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL123292 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL123292 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL123292 CHEMBL1909108 (2)
0 / 0
Q96RI1 Bile acid receptor NR1H4 CHEMBL123292 CHEMBL1794437 (1)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL123292 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL123292 CHEMBL1552697 CHEMBL1613808 (1) CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL123292 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL123292 CHEMBL1078564 CHEMBL1358722 CHEMBL1741322 (2) CHEMBL1909132 (2)
0 / 0
P27540 Aryl hydrocarbon receptor nuclear translocator Unclassified protein CHEMBL123292 CHEMBL999908 (1) CHEMBL999909 (1)
0 / 0
O15118 Niemann-Pick C1 protein Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL1614342 (2)
1 / 1
P51449 Nuclear receptor ROR-gamma Nuclear hormone receptor subfamily 1 group F member 3 CHEMBL123292 CHEMBL2114842 (2)
0 / 0
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL1738588 (2)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL123292 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL123292 CHEMBL1794542 (3) CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909091 (2)
1 / 0
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A Isomerase CHEMBL123292 CHEMBL678140 (1) CHEMBL678144 (1)
0 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL123292 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL123292 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL123292 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL123292 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL123292 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL123292 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL123292 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL123292 CHEMBL1909168 (2)
0 / 0
P19838 Nuclear factor NF-kappa-B p105 subunit Transcription Factor CHEMBL123292 CHEMBL2114853 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL123292 CHEMBL1078564 CHEMBL1358722 CHEMBL1613777 (1) CHEMBL1741323 (2)
CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL123292 CHEMBL1078564 CHEMBL1358722 CHEMBL1614108 (1) CHEMBL1613886 (1)
CHEMBL1741324 (2) CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL123292 CHEMBL1909137 (2)
0 / 0
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL1738184 (2) CHEMBL2114890 (3)
0 / 0
P10275 Androgen receptor NR3C4 CHEMBL123292 CHEMBL1794321 (3) CHEMBL1794560 (2)
3 / 4
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL123292 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL123292 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL123292 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL123292 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL123292 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL123292 CHEMBL1909128 (2)
0 / 0
P07900 Heat shock protein HSP 90-alpha Other cytosolic protein CHEMBL123292 CHEMBL1358722 CHEMBL1794333 (2)
0 / 0
P68104 Elongation factor 1-alpha 1 Unclassified protein CHEMBL123292 CHEMBL1228364 (1)
0 / 0
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL123292 CHEMBL1358722 CHEMBL2354311 (2)
1 / 0
Q13148 TAR DNA-binding protein 43 Unclassified protein CHEMBL123292 CHEMBL1358722 CHEMBL2354287 (2)
1 / 1

CTD interaction (550)

compound gene gene name gene description interaction interaction type form reference
pmid
D003513 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA] increases expression
/ increases reaction
mRNA 7476894
D003513 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Cycloheximide results in increased expression of ABCB1 mRNA increases expression
mRNA 7476894
D003513 5244 ABCB4
ABC21
GBD1
ICP3
MDR2
MDR2/3
MDR3
PFIC-3
PGY3
ATP-binding cassette, sub-family B (MDR/TAP), member 4 (EC:3.6.3.44) Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA] decreases expression
/ decreases reaction
mRNA 11331069
D003513 8714 ABCC3
ABC31
EST90757
MLP2
MOAT-D
MRP3
cMOAT2
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 [Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 8714 ABCC3
ABC31
EST90757
MLP2
MOAT-D
MRP3
cMOAT2
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Cycloheximide results in increased expression of ABCC3 mRNA increases expression
mRNA 15072547
D003513 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 [Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA affects cotreatment
/ decreases expression
mRNA 15072547
D003513 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 Cycloheximide results in decreased expression of ABCC5 mRNA decreases expression
mRNA 15072547
D003513 2181 ACSL3
ACS3
FACL3
PRO2194
acyl-CoA synthetase long-chain family member 3 (EC:6.2.1.3) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA affects cotreatment
/ affects expression
mRNA 19684285
D003513 8754 ADAM9
CORD9
MCMP
MDC9
Mltng
ADAM metallopeptidase domain 9 Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein] decreases reaction
/ increases expression
protein 17018608
D003513 133 ADM
AM
adrenomedullin Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA] increases expression
/ increases reaction
mRNA 11032871
D003513 133 ADM
AM
adrenomedullin Cycloheximide results in increased expression of ADM mRNA increases expression
mRNA 11032871
D003513 136 ADORA2B
ADORA2
adenosine A2b receptor [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 196 AHR
bHLHe76
aryl hydrocarbon receptor benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein] decreases expression
/ decreases reaction
protein 15385644
D003513 196 AHR
bHLHe76
aryl hydrocarbon receptor Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA] decreases expression
/ decreases reaction
mRNA 9145908
D003513 196 AHR
bHLHe76
aryl hydrocarbon receptor Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein] decreases expression
/ increases degradation
/ increases reaction
protein 15385644
D003513 196 AHR
bHLHe76
aryl hydrocarbon receptor Cycloheximide results in decreased expression of AHR protein decreases expression
protein 15385644
D003513 9495 AKAP5
AKAP75
AKAP79
H21
A kinase (PRKA) anchor protein 5 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 9472 AKAP6
ADAP100
ADAP6
AKAP100
PRKA6
mAKAP
A kinase (PRKA) anchor protein 6 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 220 ALDH1A3
ALDH1A6
ALDH6
MCOP8
RALDH3
aldehyde dehydrogenase 1 family, member A3 (EC:1.2.1.5) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 224 ALDH3A2
ALDH10
FALDH
SLS
aldehyde dehydrogenase 3 family, member A2 (EC:1.2.1.3) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 241 ALOX5AP
FLAP
arachidonate 5-lipoxygenase-activating protein Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 248 ALPI
IAP
alkaline phosphatase, intestinal (EC:3.1.3.1) Cycloheximide results in decreased activity of ALPI protein decreases activity
protein 20362602
D003513 269 AMHR2
AMHR
MISR2
MISRII
MRII
anti-Mullerian hormone receptor, type II (EC:2.7.11.30) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 287 ANK2
ANK-2
LQT4
brank-2
ankyrin 2, neuronal Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 84079 ANKRD27
VARP
ankyrin repeat domain 27 (VPS9 domain) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 317 APAF1
APAF-1
CED4
apoptotic peptidase activating factor 1 Cycloheximide results in decreased expression of APAF1 mRNA decreases expression
mRNA 19684285
D003513 317 APAF1
APAF-1
CED4
apoptotic peptidase activating factor 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 374 AREG
AR
CRDGF
SDGF
amphiregulin [Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 374 AREG
AR
CRDGF
SDGF
amphiregulin Cycloheximide results in increased expression of AREG mRNA increases expression
mRNA 15072547
15228094
D003513 79798 ARMC5
armadillo repeat containing 5 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 51665 ASB1
ASB-1
ankyrin repeat and SOCS box containing 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein] decreases reaction
/ increases expression
protein 18533110
D003513 552 AVPR1A
AVPR_V1a
AVPR1
V1aR
arginine vasopressin receptor 1A Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 8424 BBOX1
BBH
BBOX
G-BBH
gamma-BBH
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 (EC:1.14.11.1) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 11726273
D003513 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Cycloheximide results in increased expression of BCL2L1 protein alternative form increases expression
protein 9326359
D003513 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein] decreases reaction
/ increases expression
protein 9326359
D003513 79370 BCL2L14
BCLG
BCL2-like 14 (apoptosis facilitator) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 622 BDH1
BDH
SDR9C1
3-hydroxybutyrate dehydrogenase, type 1 (EC:1.1.1.30) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein] decreases reaction
/ increases expression
protein 16882451
D003513 637 BID
FP497
BH3 interacting domain death agonist [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 12925536
D003513 637 BID
FP497
BH3 interacting domain death agonist Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein] decreases reaction
/ increases cleavage
protein 11535817
D003513 637 BID
FP497
BH3 interacting domain death agonist ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 12925536
D003513 637 BID
FP497
BH3 interacting domain death agonist ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] affects cotreatment
/ increases cleavage
/ increases reaction
protein 12925536
D003513 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] decreases expression
/ decreases reaction
mRNA 10344722
D003513 675 BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCB
FANCD
FANCD1
GLM3
PNCA2
breast cancer 2, early onset Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] decreases expression
/ decreases reaction
mRNA 10344722
D003513 90488 C12orf23
chromosome 12 open reading frame 23 Cycloheximide results in increased expression of C12ORF23 mRNA increases expression
mRNA 19684285
D003513 90488 C12orf23
chromosome 12 open reading frame 23 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of C12ORF23 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 793 CALB1
CALB
calbindin 1, 28kDa Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 819 CAMLG
CAML
calcium modulating ligand Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 834 CASP1
ICE
IL1BC
P45
caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 18222423
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 12925536
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 12760867
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Cycloheximide results in increased activity of CASP3 protein increases activity
protein 15685448
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 15685448
D003513 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 12925536
D003513 837 CASP4
ICE(rel)II
ICEREL-II
ICH-2
Mih1/TX
TX
caspase 4, apoptosis-related cysteine peptidase (EC:3.4.22.57) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA] decreases reaction
/ increases expression
mRNA 16166294
D003513 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein] increases activity
/ increases reaction
protein 12760867
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 18222423
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 12925536
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 18222423
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] increases activity
/ increases reaction
protein 12760867
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Cycloheximide results in increased activity of CASP8 protein increases activity
protein 15924153
D003513 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 12925536
D003513 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 12925536
D003513 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 18222423
D003513 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 12925536
D003513 857 CAV1
BSCL3
CGL3
MSTP085
PPH3
VIP21
CAV
caveolin 1, caveolae protein, 22kDa Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA] decreases reaction
/ increases expression
mRNA 15314095
D003513 10951 CBX1
CBX
HP1-BETA
HP1Hs-beta
HP1Hsbeta
M31
MOD1
p25beta
chromobox homolog 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Cycloheximide results in increased expression of CCL2 mRNA increases expression
mRNA 21146893
D003513 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA] increases expression
/ increases reaction
mRNA 21146893
D003513 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21146893
D003513 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 Cycloheximide results in increased expression of CCL5 mRNA increases expression
mRNA 21146893
D003513 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA] increases expression
/ increases reaction
mRNA 21146893
D003513 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21146893
D003513 890 CCNA2
CCN1
CCNA
cyclin A2 [Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 890 CCNA2
CCN1
CCNA
cyclin A2 Cycloheximide results in decreased expression of CCNA2 mRNA decreases expression
mRNA 15072547
D003513 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Cycloheximide inhibits the reaction [IL8 protein results in increased expression of CCND1 protein] decreases reaction
/ increases expression
protein 17606477
D003513 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein affects cotreatment
/ increases degradation
protein 18058799
D003513 22948 CCT5
CCT-epsilon
CCTE
TCP-1-epsilon
chaperonin containing TCP1, subunit 5 (epsilon) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 952 CD38
T10
CD38 molecule (EC:3.2.2.5) Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA] affects reaction
/ increases expression
mRNA 21393419
D003513 916 CD3E
T3E
TCRE
CD3e molecule, epsilon (CD3-TCR complex) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 961 CD47
IAP
MER6
OA3
CD47 molecule Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 967 CD63
LAMP-3
ME491
MLA1
OMA81H
TSPAN30
CD63 molecule Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 925 CD8A
CD8
Leu2
MAL
p32
CD8a molecule [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 56990 CDC42SE2
SPEC2
CDC42 small effector 2 Cycloheximide results in increased expression of CDC42SE2 mRNA increases expression
mRNA 19684285
D003513 56990 CDC42SE2
SPEC2
CDC42 small effector 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA affects cotreatment
/ affects expression
mRNA 19684285
D003513 113130 CDCA5
SORORIN
cell division cycle associated 5 Cycloheximide results in increased expression of CDCA5 mRNA increases expression
mRNA 19684285
D003513 113130 CDCA5
SORORIN
cell division cycle associated 5 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA] decreases expression
/ decreases reaction
mRNA 12800980
D003513 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Cycloheximide inhibits the reaction [resveratrol results in increased expression of CDKN1A mRNA] decreases reaction
/ increases expression
mRNA 12690110
D003513 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Cycloheximide inhibits the reaction [troglitazone results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 10441511
D003513 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A Cycloheximide results in increased expression of CDKN2A mRNA increases expression
mRNA 17257637
D003513 8837 CFLAR
CASH
CASP8AP1
CLARP
Casper
FLAME
FLAME-1
FLAME1
FLIP
I-FLICE
MRIT
c-FLIP
c-FLIPL
c-FLIPR
c-FLIPS
CASP8 and FADD-like apoptosis regulator Cycloheximide results in decreased expression of CFLAR protein decreases expression
protein 12663669
16077199
16951203
D003513 8837 CFLAR
CASH
CASP8AP1
CLARP
Casper
FLAME
FLAME-1
FLAME1
FLIP
I-FLICE
MRIT
c-FLIP
c-FLIPL
c-FLIPR
c-FLIPS
CASP8 and FADD-like apoptosis regulator Cycloheximide results in decreased expression of CFLAR protein alternative form decreases expression
protein 15924153
D003513 1128 CHRM1
HM1
M1
M1R
cholinergic receptor, muscarinic 1 Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA] decreases expression
/ decreases reaction
mRNA 17624924
D003513 10370 CITED2
ASD8
MRG-1
MRG1
P35SRJ
VSD2
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA affects cotreatment
/ affects expression
mRNA 19684285
D003513 1182 CLCN3
CLC3
ClC-3
chloride channel, voltage-sensitive 3 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1268 CNR1
CANN6
CB-R
CB1
CB1A
CB1K5
CB1R
CNR
cannabinoid receptor 1 (brain) Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA] decreases reaction
/ increases expression
mRNA 17041005
D003513 51084 CRYL1
GDH
lambda-CRY
crystallin, lambda 1 (EC:1.1.1.45) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein] decreases reaction
/ increases secretion
protein 9606035
D003513 1453 CSNK1D
ASPS
CKIdelta
FASPS2
HCKID
casein kinase 1, delta (EC:2.7.11.1 2.7.11.26) Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA] decreases expression
/ increases reaction
mRNA 11007951
D003513 1490 CTGF
CCN2
HCS24
IGFBP8
NOV2
connective tissue growth factor Cycloheximide results in increased expression of CTGF mRNA increases expression
mRNA 19684285
D003513 1490 CTGF
CCN2
HCS24
IGFBP8
NOV2
connective tissue growth factor [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CTGF mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 1588 CYP19A1
ARO
ARO1
CPV1
CYAR
CYP19
CYPXIX
P-450AROM
cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide results in decreased activity of CYP19A1 protein decreases activity
protein 16480277
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) 3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 15385644
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 15385644
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] increases expression
/ increases reaction
mRNA 8647108
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 22037238
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 22037238
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] increases expression
/ increases reaction
mRNA 8647108
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein affects cotreatment
/ decreases expression
protein 22037238
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein affects cotreatment
/ decreases expression
protein 22037238
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA affects cotreatment
/ increases expression
mRNA 15385644
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]] decreases reaction
/ increases expression
mRNA 9145908
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA] increases expression
/ increases reaction
mRNA 20187624
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] increases expression
/ increases reaction
mRNA 9102211
17599377
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Cycloheximide results in increased expression of CYP1A1 mRNA increases expression
mRNA 8647108
15385644
19244278
19684285
D003513 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] decreases reaction
/ increases expression
mRNA 9145908
D003513 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) Cycloheximide results in increased expression of CYP1B1 mRNA increases expression
mRNA 19684285
D003513 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1591 CYP24A1
CP24
CYP24
HCAI
P450-CC24
cytochrome P450, family 24, subfamily A, polypeptide 1 (EC:1.14.13.126) alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 19244278
D003513 1591 CYP24A1
CP24
CYP24
HCAI
P450-CC24
cytochrome P450, family 24, subfamily A, polypeptide 1 (EC:1.14.13.126) Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] decreases reaction
/ increases expression
mRNA 19244278
D003513 1548 CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) Bilirubin inhibits the reaction [Cycloheximide results in decreased expression of CYP2A6 protein] decreases expression
/ decreases reaction
protein 22465937
D003513 1548 CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) Cycloheximide results in decreased expression of CYP2A6 protein decreases expression
protein 22465937
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) (4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] increases degradation
/ increases reaction
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] decreases reaction
/ increases oxidation
protein 8531136
9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]] decreases reaction
/ increases oxidation
/ increases reaction
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein] increases degradation
/ increases reaction
protein 8531136
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Cycloheximide results in increased degradation of CYP2E1 protein increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]] decreases reaction
/ increases oxidation
protein 8531136
D003513 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] decreases reaction
/ increases degradation
protein 9143349
D003513 1572 CYP2F1
C2F1
CYP2F
cytochrome P450, family 2, subfamily F, polypeptide 1 (EC:1.14.14.1) Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA] decreases reaction
/ increases expression
mRNA 20187624
D003513 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Cycloheximide results in decreased expression of CYP3A4 mRNA decreases expression
mRNA 21466820
D003513 3491 CYR61
CCN1
GIG1
IGFBP10
cysteine-rich, angiogenic inducer, 61 Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CYR61 protein] decreases reaction
/ increases expression
protein 21055460
D003513 1605 DAG1
156DAG
A3a
AGRNR
DAG
MDDGC7
MDDGC9
dystroglycan 1 (dystrophin-associated glycoprotein 1) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 1634 DCN
CSCD
DSPG2
PG40
PGII
PGS2
SLRR1B
decorin Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10522 DEAF1
NUDR
SPN
ZMYND5
DEAF1 transcription factor [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 8560 DEGS1
DEGS
DEGS-1
DES1
Des-1
FADS7
MLD
delta(4)-desaturase, sphingolipid 1 (EC:1.14.-.-) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 1734 DIO2
5DII
D2
DIOII
SelY
TXDI2
deiodinase, iodothyronine, type II (EC:1.97.1.10) benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein] decreases activity
/ decreases reaction
protein 11425850
D003513 1734 DIO2
5DII
D2
DIOII
SelY
TXDI2
deiodinase, iodothyronine, type II (EC:1.97.1.10) Cycloheximide results in decreased activity of DIO2 protein decreases activity
protein 11425850
D003513 1734 DIO2
5DII
D2
DIOII
SelY
TXDI2
deiodinase, iodothyronine, type II (EC:1.97.1.10) lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein] decreases activity
/ decreases reaction
protein 11425850
D003513 8847 DLEU2
1B4
BCMSUN
DLB2
LEU2
LINC00022
MIR15AHG
NCRNA00022
RFP2OS
TRIM13OS
deleted in lymphocytic leukemia 2 (non-protein coding) [Cycloheximide co-treated with Estradiol] results in increased expression of DLEU2 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 8847 DLEU2
1B4
BCMSUN
DLB2
LEU2
LINC00022
MIR15AHG
NCRNA00022
RFP2OS
TRIM13OS
deleted in lymphocytic leukemia 2 (non-protein coding) Cycloheximide results in increased expression of DLEU2 mRNA increases expression
mRNA 15072547
D003513 25822 DNAJB5
Hsc40
DnaJ (Hsp40) homolog, subfamily B, member 5 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10059 DNM1L
DLP1
DRP1
DVLP
DYMPLE
EMPF
HDYNIV
dynamin 1-like (EC:3.6.5.5) Cycloheximide results in increased expression of DNM1L mRNA increases expression
mRNA 19684285
D003513 10059 DNM1L
DLP1
DRP1
DVLP
DYMPLE
EMPF
HDYNIV
dynamin 1-like (EC:3.6.5.5) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Cycloheximide results in increased expression of EGFR mRNA increases expression
mRNA 15228094
D003513 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA] decreases reaction
/ increases expression
mRNA 12690110
D003513 1959 EGR2
AT591
CMT1D
CMT4E
KROX20
early growth response 2 Cycloheximide results in increased expression of EGR2 mRNA increases expression
mRNA 19350554
D003513 83939 EIF2A
EIF-2A
MST089
MSTP004
MSTP089
eukaryotic translation initiation factor 2A, 65kDa Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] decreases reaction
/ increases phosphorylation
protein 17283163
D003513 1965 EIF2S1
EIF-2
EIF-2A
EIF-2alpha
EIF2
EIF2A
eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa Cycloheximide results in increased expression of EIF2S1 mRNA increases expression
mRNA 19684285
D003513 1965 EIF2S1
EIF-2
EIF-2A
EIF-2alpha
EIF2
EIF2A
eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 8672 EIF4G3
eIF-4G_3
eIF4G_3
eIF4GII
eukaryotic translation initiation factor 4 gamma, 3 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 1983 EIF5
EIF-5
EIF-5A
eukaryotic translation initiation factor 5 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 2000 ELF4
ELFR
MEF
E74-like factor 4 (ets domain transcription factor) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 2002 ELK1
ELK1, member of ETS oncogene family Cycloheximide results in increased expression of ELK1 mRNA increases expression
mRNA 19684285
D003513 2002 ELK1
ELK1, member of ETS oncogene family [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 8507 ENC1
CCL28
ENC-1
KLHL35
KLHL37
NRPB
PIG10
TP53I10
ectodermal-neural cortex 1 (with BTB domain) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 2021 ENDOG
endonuclease G Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 1833 EPYC
DSPG3
PGLB
Pg-Lb
SLRR3B
epiphycan Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA affects cotreatment
/ decreases expression
mRNA 15072547
D003513 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) Cycloheximide results in decreased expression of ERBB2 mRNA decreases expression
mRNA 15072547
15228094
D003513 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) Cycloheximide results in decreased expression of ERBB2 protein decreases expression
protein 20379846
D003513 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] decreases expression
/ increases reaction
protein 20379846
D003513 2065 ERBB3
ErbB-3
HER3
LCCS2
MDA-BF-1
c-erbB-3
c-erbB3
erbB3-S
p180-ErbB3
p45-sErbB3
p85-sErbB3
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (EC:2.7.10.1) Cycloheximide results in decreased expression of ERBB3 mRNA decreases expression
mRNA 15228094
D003513 2069 EREG
ER
epiregulin Cycloheximide results in increased expression of EREG mRNA increases expression
mRNA 15228094
D003513 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] increases expression
/ increases reaction
mRNA 15207704
D003513 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 15207704
D003513 2132 EXT2
SOTV
exostosin glycosyltransferase 2 (EC:2.4.1.225 2.4.1.224) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2161 F12
HAE3
HAEX
HAF
coagulation factor XII (Hageman factor) (EC:3.4.21.38) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein] decreases activity
/ decreases reaction
protein 14630613
D003513 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 12760867
D003513 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein] increases activity
/ increases reaction
protein 12760867
D003513 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] increases activity
/ increases reaction
protein 12760867
D003513 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2194 FASN
FAS
OA-519
SDR27X1
fatty acid synthase (EC:2.3.1.85 2.3.1.38 2.3.1.39 2.3.1.41 3.1.2.14 4.2.1.59 1.1.1.100 1.3.1.39) Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA] decreases expression
/ decreases reaction
mRNA 12798352
D003513 2091 FBL
FIB
FLRN
RNU3IP1
fibrillarin [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 10875 FGL2
T49
pT49
fibrinogen-like 2 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2272 FHIT
AP3Aase
FRA3B
fragile histidine triad (EC:3.6.1.29) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 2277 FIGF
VEGF-D
VEGFD
c-fos induced growth factor (vascular endothelial growth factor D) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FIGF mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2332 FMR1
FMRP
FRAXA
POF
POF1
fragile X mental retardation 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein] decreases reaction
/ increases expression
protein 15090535
D003513 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein] decreases reaction
/ increases expression
protein 15090535
D003513 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein] decreases reaction
/ increases expression
protein 15090535
D003513 2444 FRK
GTK
PTK5
RAK
fyn-related kinase (EC:2.7.10.2) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10468 FST
FS
follistatin Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 2526 FUT4
CD15
ELFT
FCT3A
FUC-TIV
FUTIV
LeX
SSEA-1
fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific) (EC:2.4.1.-) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 8324 FZD7
FzE3
frizzled family receptor 7 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2589 GALNT1
GALNAC-T1
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) (EC:2.4.1.41) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 2619 GAS1
growth arrest-specific 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 9518 GDF15
GDF-15
MIC-1
MIC1
NAG-1
PDF
PLAB
PTGFB
growth differentiation factor 15 Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA] affects expression
/ decreases reaction
mRNA 18801729
D003513 9518 GDF15
GDF-15
MIC-1
MIC1
NAG-1
PDF
PLAB
PTGFB
growth differentiation factor 15 Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein] affects expression
/ decreases reaction
protein 18801729
D003513 9518 GDF15
GDF-15
MIC-1
MIC1
NAG-1
PDF
PLAB
PTGFB
growth differentiation factor 15 Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA] decreases reaction
/ increases expression
mRNA 14662774
D003513 8733 GPAA1
GAA1
hGAA1
glycosylphosphatidylinositol anchor attachment 1 Cycloheximide results in increased expression of GPAA1 mRNA increases expression
mRNA 19684285
D003513 8733 GPAA1
GAA1
hGAA1
glycosylphosphatidylinositol anchor attachment 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 2861 GPR37
EDNRBL
PAELR
hET(B)R-LP
G protein-coupled receptor 37 (endothelin receptor type B-like) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 2896 GRN
CLN11
GEP
GP88
PCDGF
PEPI
PGRN
granulin [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 1839 HBEGF
DTR
DTS
DTSF
HEGFL
heparin-binding EGF-like growth factor Cycloheximide results in increased expression of HBEGF mRNA increases expression
mRNA 15228094
D003513 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 20524035
D003513 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 11641398
D003513 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form] decreases reaction
/ increases expression
protein 11739637
D003513 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Cycloheximide results in increased degradation of HIF1A protein increases degradation
protein 11641398
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 18357586
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA] decreases reaction
/ increases expression
mRNA 19781563
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 19781563
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 21840424
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 mRNA] decreases reaction
/ increases expression
mRNA 15588712
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 15588712
D003513 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein] decreases response to substance
/ increases expression
protein 20833156
D003513 3188 HNRNPH2
FTP3
HNRPH'
HNRPH2
hnRNPH'
heterogeneous nuclear ribonucleoprotein H2 (H') Cycloheximide results in increased expression of HNRNPH2 mRNA increases expression
mRNA 19684285
D003513 10553 HTATIP2
CC3
SDR44U1
TIP30
HIV-1 Tat interactive protein 2, 30kDa (EC:1.1.1.-) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 16087364
D003513 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Cycloheximide results in decreased expression of ICAM1 protein decreases expression
protein 16087364
D003513 8870 IER3
DIF-2
DIF2
GLY96
IEX-1
IEX-1L
IEX1
PRG1
immediate early response 3 [hydroxytamoxifen co-treated with Cycloheximide] results in increased expression of IER3 mRNA affects cotreatment
/ increases expression
mRNA 16849584
D003513 2537 IFI6
6-16
FAM14C
G1P3
IFI-6-16
IFI616
interferon, alpha-inducible protein 6 IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 15685448
D003513 3440 IFNA2
IFN-alphaA
IFNA
IFNA2B
INFA2
interferon, alpha 2 [Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA affects cotreatment
/ increases expression
protein 12070711
D003513 3458 IFNG
IFG
IFI
interferon, gamma [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA affects cotreatment
/ increases expression
protein 12070711
D003513 3458 IFNG
IFG
IFI
interferon, gamma Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 16087364
D003513 3458 IFNG
IFG
IFI
interferon, gamma Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] decreases reaction
/ increases expression
protein 16087364
D003513 11020 IFT27
RABL4
RAYL
intraflagellar transport 27 homolog (Chlamydomonas) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 3487 IGFBP4
BP-4
HT29-IGFBP
IBP4
IGFBP-4
insulin-like growth factor binding protein 4 [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 3487 IGFBP4
BP-4
HT29-IGFBP
IBP4
IGFBP-4
insulin-like growth factor binding protein 4 Cycloheximide results in increased expression of IGFBP4 mRNA increases expression
mRNA 15072547
D003513 3552 IL1A
IL-1A
IL1
IL1-ALPHA
IL1F1
interleukin 1, alpha Cycloheximide results in increased expression of IL1A mRNA increases expression
mRNA 19684285
D003513 3552 IL1A
IL-1A
IL1
IL1-ALPHA
IL1F1
interleukin 1, alpha [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 11112151
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 11112151
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein] decreases reaction
/ increases secretion
9606035
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cycloheximide inhibits the reaction [IL8 protein affects the secretion of IL1B protein] affects secretion
/ decreases reaction
protein 8071060
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cycloheximide results in increased expression of IL1B mRNA increases expression
mRNA 19684285
D003513 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Cycloheximide inhibits the reaction [IL8 protein affects the secretion of IL6 protein] affects secretion
/ decreases reaction
protein 8071060
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Cycloheximide results in decreased secretion of IL6 protein decreases secretion
protein 11216681
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Cycloheximide results in increased expression of IL6 mRNA increases expression
mRNA 21146893
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Cycloheximide results in increased secretion of IL6 protein increases secretion
protein 21146893
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA] increases expression
/ increases reaction
mRNA 21146893
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein] increases reaction
/ increases secretion
protein 21146893
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21146893
D003513 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] decreases reaction
/ increases reaction
/ increases secretion
protein 21146893
D003513 3572 IL6ST
CD130
CDW130
GP130
IL-6RB
interleukin 6 signal transducer (gp130, oncostatin M receptor) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [cadmium sulfate results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 22094458
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [deoxynivalenol results in increased expression of IL8 protein] decreases reaction
/ increases expression
protein 18308354
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [IL8 protein affects the secretion of IL1B protein] affects secretion
/ decreases reaction
protein 8071060
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [IL8 protein affects the secretion of IL6 protein] affects secretion
/ decreases reaction
protein 8071060
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [IL8 protein affects the secretion of TNF protein] affects secretion
/ decreases reaction
protein 8071060
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [IL8 protein results in increased expression of CCND1 protein] decreases reaction
/ increases expression
protein 17606477
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [Zinc deficiency results in decreased expression of IL8 protein]] decreases expression
/ decreases reaction
protein 12812920
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL8 protein] decreases reaction
/ increases expression
protein 12812920
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Cycloheximide results in increased expression of IL8 mRNA increases expression
mRNA 21146893
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein affects cotreatment
/ increases secretion
protein 21146893
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA] increases expression
/ increases reaction
mRNA 21146893
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 21146893
D003513 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21146893
D003513 8826 IQGAP1
HUMORFA01
SAR1
p195
IQ motif containing GTPase activating protein 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3667 IRS1
HIRS-1
insulin receptor substrate 1 [Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 3667 IRS1
HIRS-1
insulin receptor substrate 1 Cycloheximide results in decreased expression of IRS1 mRNA decreases expression
mRNA 15072547
D003513 3690 ITGB3
BDPLT16
BDPLT2
CD61
GP3A
GPIIIa
GT
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3694 ITGB6
integrin, beta 6 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3694 ITGB6
integrin, beta 6 Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] decreases reaction
/ increases expression
mRNA 21303922
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] affects cotreatment
/ decreases reaction
/ increases activity
12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein] affects cotreatment
/ decreases reaction
/ increases cleavage
12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] affects cotreatment
/ increases cleavage
/ increases reaction
mutant form 12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] affects cotreatment
/ increases cleavage
/ increases reaction
mutant form 12925536
D003513 3705 ITPK1
ITRPK1
inositol-tetrakisphosphate 1-kinase (EC:2.7.1.134 2.7.1.159) ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein] affects cotreatment
/ increases response to substance
mutant form 12925536
D003513 3708 ITPR1
INSP3R1
IP3R
IP3R1
SCA15
SCA16
SCA29
inositol 1,4,5-trisphosphate receptor, type 1 Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA] decreases reaction
/ increases expression
mRNA 17241155
D003513 3708 ITPR1
INSP3R1
IP3R
IP3R1
SCA15
SCA16
SCA29
inositol 1,4,5-trisphosphate receptor, type 1 Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA] decreases reaction
/ increases expression
mRNA 17241155
D003513 3708 ITPR1
INSP3R1
IP3R
IP3R1
SCA15
SCA16
SCA29
inositol 1,4,5-trisphosphate receptor, type 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 23189 KANK1
ANKRD15
CPSQ2
KANK
KN motif and ankyrin repeat domains 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 23313 C22orf9
KIAA0930 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3860 KRT13
CK13
K13
keratin 13 [hydroxytamoxifen co-treated with Cycloheximide] results in increased expression of KRT13 mRNA affects cotreatment
/ increases expression
mRNA 16849584
D003513 200185 KRTCAP2
KCP2
keratinocyte associated protein 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 3932 LCK
LSK
YT16
p56lck
pp58lck
lymphocyte-specific protein tyrosine kinase (EC:2.7.10.2) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 3958 LGALS3
CBP35
GAL3
GALBP
GALIG
L31
LGALS2
MAC2
lectin, galactoside-binding, soluble, 3 Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein] decreases reaction
/ increases expression
protein 21821001
D003513 4008 LMO7
FBX20
FBXO20
LOMP
LIM domain 7 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 9404 LPXN
LDPL
leupaxin Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Cycloheximide results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 15087236
D003513 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein] affects reaction
/ increases phosphorylation
protein 15087236
D003513 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein] decreases phosphorylation
/ decreases reaction
protein 17507666
D003513 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Cycloheximide results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 15087236
D003513 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] affects reaction
/ increases phosphorylation
protein 15087236
D003513 5598 MAPK7
BMK1
ERK4
ERK5
PRKM7
mitogen-activated protein kinase 7 (EC:2.7.11.24) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5598 MAPK7
BMK1
ERK4
ERK5
PRKM7
mitogen-activated protein kinase 7 (EC:2.7.11.24) Cycloheximide results in increased expression of MAPK7 mRNA increases expression
mRNA 19684285
D003513 5598 MAPK7
BMK1
ERK4
ERK5
PRKM7
mitogen-activated protein kinase 7 (EC:2.7.11.24) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737 affects cotreatment
/ increases response to substance
21880625
D003513 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) Cycloheximide results in decreased expression of MCL1 protein decreases expression
protein 14982947
D003513 4192 MDK
ARAP
MK
NEGF2
midkine (neurite growth-promoting factor 2) Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA] decreases expression
/ increases reaction
mRNA 11007951
D003513 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA] decreases reaction
/ increases expression
mRNA 23052036
D003513 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA] decreases expression
/ decreases reaction
mRNA 19264808
D003513 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA] decreases reaction
/ increases expression
mRNA 23052036
D003513 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] decreases reaction
/ increases expression
mRNA 23052036
D003513 406991 MIR21
MIRN21
hsa-mir-21
miR-21
miRNA21
microRNA 21 Cycloheximide results in increased expression of MIR21 mRNA increases expression
mRNA 23052036
D003513 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein] decreases reaction
/ increases expression
protein 19136476
D003513 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA] decreases reaction
/ increases expression
mRNA 15075337
D003513 4322 MMP13
CLG3
MANDP1
matrix metallopeptidase 13 (collagenase 3) (EC:3.4.24.-) Cycloheximide results in increased expression of MMP13 mRNA increases expression
mRNA 19684285
D003513 4322 MMP13
CLG3
MANDP1
matrix metallopeptidase 13 (collagenase 3) (EC:3.4.24.-) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 3110 MNX1
HB9
HLXB9
HOXHB9
SCRA1
motor neuron and pancreas homeobox 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 4350 MPG
AAG
ADPG
APNG
CRA36.1
MDG
Mid1
PIG11
PIG16
anpg
N-methylpurine-DNA glycosylase (EC:3.2.2.21) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 51081 MRPS7
MRP-S
MRP-S7
RP-S7
RPMS7
S7mt
bMRP27a
mitochondrial ribosomal protein S7 Cycloheximide results in decreased expression of MRPS7 mRNA decreases expression
mRNA 19684285
D003513 51081 MRPS7
MRP-S
MRP-S7
RP-S7
RPMS7
S7mt
bMRP27a
mitochondrial ribosomal protein S7 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA affects cotreatment
/ affects expression
mRNA 19684285
D003513 4437 MSH3
DUP
MRP1
mutS homolog 3 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 4481 MSR1
CD204
SCARA1
SR-A
SRA
phSR1
phSR2
macrophage scavenger receptor 1 Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] decreases reaction
/ increases expression
mRNA 9614211
D003513 23788 MTCH2
MIMP
SLC25A50
mitochondrial carrier 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 9108 MTMR7
myotubularin related protein 7 (EC:3.1.3.-) Cycloheximide results in increased expression of MTMR7 mRNA increases expression
mRNA 19684285
D003513 9108 MTMR7
myotubularin related protein 7 (EC:3.1.3.-) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4084 MXD1
BHLHC58
MAD
MAD1
MAX dimerization protein 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 83463 MXD3
BHLHC13
MAD3
MYX
MAX dimerization protein 3 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4638 MYLK
AAT7
KRP
MLCK
MLCK1
MLCK108
MLCK210
MSTP083
MYLK1
smMLCK
myosin light chain kinase (EC:2.7.11.18) Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] decreases reaction
/ increases expression
protein 15701621
D003513 4077 NBR1
1A1-3B
M17S2
neighbor of BRCA1 gene 1 Cycloheximide results in increased expression of NBR1 mRNA increases expression
mRNA 19684285
D003513 4077 NBR1
1A1-3B
M17S2
neighbor of BRCA1 gene 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4751 NEK2
HsPK21
NEK2A
NLK1
NIMA-related kinase 2 (EC:2.7.11.1) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]] affects localization
/ affects reaction
/ decreases reaction
protein 22197970
D003513 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 22197970
D003513 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 Cycloheximide inhibits the reaction [sulforafan results in increased expression of NFE2L2 protein] decreases reaction
/ increases expression
protein 22019695
D003513 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 22197970
D003513 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Cycloheximide affects the localization of NFKB1 protein affects localization
protein 16637064
D003513 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] affects binding
/ decreases expression
protein 16637064
D003513 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Cycloheximide results in increased expression of NFKB1 mRNA increases expression
mRNA 21146893
D003513 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA] increases expression
/ increases reaction
mRNA 21146893
D003513 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21146893
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein] decreases expression
/ increases reaction
protein 15330761
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] increases degradation
/ increases reaction
protein 15330761
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cycloheximide results in decreased expression of NFKBIA protein decreases expression
protein 15330761
16637064
21692457
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cycloheximide results in increased degradation of NFKBIA protein increases degradation
protein 15330761
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]] affects reaction
/ increases expression
/ increases reaction
protein 16637064
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein] decreases expression
/ increases reaction
protein 15330761
D003513 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein] increases degradation
/ increases reaction
protein 15330761
D003513 4843 NOS2
HEP-NOS
INOS
NOS
NOS2A
nitric oxide synthase 2, inducible (EC:1.14.13.39) Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein] decreases reaction
/ increases expression
protein 10760090
D003513 4843 NOS2
HEP-NOS
INOS
NOS
NOS2A
nitric oxide synthase 2, inducible (EC:1.14.13.39) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 4856 NOV
CCN3
IBP-9
IGFBP-9
IGFBP9
NOVh
nephroblastoma overexpressed [Cycloheximide co-treated with Estradiol] results in decreased expression of NOV mRNA affects cotreatment
/ decreases expression
mRNA 15072547
D003513 4856 NOV
CCN3
IBP-9
IGFBP-9
IGFBP9
NOVh
nephroblastoma overexpressed Cycloheximide results in increased expression of NOV mRNA increases expression
mRNA 15072547
D003513 4886 NPY1R
NPY1-R
NPYR
neuropeptide Y receptor Y1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10062 NR1H3
LXR-a
LXRA
RLD-1
nuclear receptor subfamily 1, group H, member 3 Cycloheximide results in increased expression of NR1H3 mRNA increases expression
mRNA 19684285
D003513 10062 NR1H3
LXR-a
LXRA
RLD-1
nuclear receptor subfamily 1, group H, member 3 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 64710 NUCKS1
NUCKS
nuclear casein kinase and cyclin-dependent kinase substrate 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4986 OPRK1
K-OR-1
KOR
KOR-1
OPRK
opioid receptor, kappa 1 Cycloheximide results in increased expression of OPRK1 mRNA increases expression
mRNA 19684285
D003513 4986 OPRK1
K-OR-1
KOR
KOR-1
OPRK
opioid receptor, kappa 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 4988 OPRM1
LMOR
M-OR-1
MOP
MOR
MOR1
OPRM
opioid receptor, mu 1 Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA] decreases reaction
/ increases expression
mRNA 16434616
D003513 5036 PA2G4
EBP1
HG4-1
p38-2G4
proliferation-associated 2G4, 38kDa PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] decreases expression
/ increases reaction
protein 20379846
D003513 5069 PAPPA
ASBABP2
DIPLA1
IGFBP-4ase
PAPA
PAPP-A
PAPPA1
pregnancy-associated plasma protein A, pappalysin 1 (EC:3.4.24.79) Cycloheximide results in increased expression of PAPPA mRNA increases expression
mRNA 19684285
D003513 5069 PAPPA
ASBABP2
DIPLA1
IGFBP-4ase
PAPA
PAPP-A
PAPPA1
pregnancy-associated plasma protein A, pappalysin 1 (EC:3.4.24.79) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 12925536
D003513 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 18222423
D003513 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Cycloheximide results in increased cleavage of PARP1 protein increases cleavage
protein 16051428
D003513 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 12925536
D003513 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] affects cotreatment
/ increases cleavage
/ increases reaction
protein 12925536
D003513 5077 PAX3
CDHS
HUP2
WS1
WS3
paired box 3 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 84759 PCGF1
2010002K04Rik
NSPC1
RNF3A-2
RNF68
polycomb group ring finger 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5111 PCNA
proliferating cell nuclear antigen Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein] decreases expression
/ decreases reaction
protein 21533478
D003513 5134 PDCD2
RP8
ZMYND7
programmed cell death 2 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5297 PI4KA
PI4K-ALPHA
PIK4CA
pi4K230
phosphatidylinositol 4-kinase, catalytic, alpha (EC:2.7.1.67) Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA] decreases expression
/ increases reaction
mRNA 11007951
D003513 5283 PIGH
GPI-H
phosphatidylinositol glycan anchor biosynthesis, class H (EC:2.4.1.198) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10026 PIGK
GPI8
phosphatidylinositol glycan anchor biosynthesis, class K (EC:3.-.-.-) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 5289 PIK3C3
VPS34
hVps34
phosphatidylinositol 3-kinase, catalytic subunit type 3 (EC:2.7.1.137) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 5294 PIK3CG
PI3CG
PI3K
PI3Kgamma
PIK3
p110gamma
p120-PI3K
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (EC:2.7.11.1 2.7.1.153) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 29990 PILRB
FDFACT1
FDFACT2
paired immunoglobin-like type 2 receptor beta [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5319 PLA2G1B
PLA2
PLA2A
PPLA2
phospholipase A2, group IB (pancreas) (EC:3.1.1.4) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5329 PLAUR
CD87
U-PAR
UPAR
URKR
plasminogen activator, urokinase receptor [Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA affects cotreatment
/ increases expression
mRNA 12070711
D003513 5329 PLAUR
CD87
U-PAR
UPAR
URKR
plasminogen activator, urokinase receptor [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA affects cotreatment
/ increases expression
mRNA 12070711
D003513 5329 PLAUR
CD87
U-PAR
UPAR
URKR
plasminogen activator, urokinase receptor Cycloheximide results in increased expression of PLAUR mRNA increases expression
mRNA 12070711
D003513 23646 PLD3
HU-K4
HUK4
phospholipase D family, member 3 (EC:3.1.4.4) Cycloheximide results in increased expression of PLD3 mRNA increases expression
mRNA 19684285
D003513 23646 PLD3
HU-K4
HUK4
phospholipase D family, member 3 (EC:3.1.4.4) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5350 PLN
CMD1P
CMH18
PLB
phospholamban Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 5366 PMAIP1
APR
NOXA
phorbol-12-myristate-13-acetate-induced protein 1 Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein] decreases reaction
/ increases expression
protein 17216584
D003513 5366 PMAIP1
APR
NOXA
phorbol-12-myristate-13-acetate-induced protein 1 Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein] decreases reaction
/ increases expression
protein 17216584
D003513 10908 PNPLA6
NTE
NTEMND
SPG39
iPLA2delta
sws
patatin-like phospholipase domain containing 6 (EC:3.1.1.5) Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein] decreases reaction
/ increases activity
protein 20380879
D003513 10908 PNPLA6
NTE
NTEMND
SPG39
iPLA2delta
sws
patatin-like phospholipase domain containing 6 (EC:3.1.1.5) Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 20380879
D003513 10908 PNPLA6
NTE
NTEMND
SPG39
iPLA2delta
sws
patatin-like phospholipase domain containing 6 (EC:3.1.1.5) Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] decreases reaction
/ increases activity
protein 20380879
D003513 56342 PPAN
BXDC3
SSF
SSF-1
SSF1
SSF2
peter pan homolog (Drosophila) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5532 PPP3CB
CALNA2
CALNB
CNA2
PP2Bbeta
protein phosphatase 3, catalytic subunit, beta isozyme (EC:3.1.3.16) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10549 PRDX4
AOE37-2
PRX-4
peroxiredoxin 4 (EC:1.11.1.15) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) Cycloheximide results in decreased expression of PRKCB mRNA decreases expression
mRNA 19684285
D003513 5579 PRKCB
PKC-beta
PKCB
PRKCB1
PRKCB2
protein kinase C, beta (EC:2.7.11.13) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5590 PRKCZ
PKC-ZETA
PKC2
protein kinase C, zeta (EC:2.7.11.13) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein] decreases reaction
/ increases expression
protein 16425225
D003513 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PTEN protein] decreases reaction
/ increases expression
protein 16425225
D003513 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 11112151
D003513 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 11112151
D003513 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] decreases reaction
/ increases activity
/ increases expression
protein 7575673
D003513 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 16894348
D003513 5764 PTN
HARP
HBGF8
HBNF
NEGF1
pleiotrophin Cycloheximide results in increased expression of PTN mRNA increases expression
mRNA 19684285
D003513 5764 PTN
HARP
HBGF8
HBNF
NEGF1
pleiotrophin [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 7803 PTP4A1
HH72
PRL-1
PRL1
PTP(CAAX1)
PTPCAAX1
protein tyrosine phosphatase type IVA, member 1 (EC:3.1.3.48) Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]] decreases reaction
/ increases expression
mRNA 19146866
D003513 7803 PTP4A1
HH72
PRL-1
PRL1
PTP(CAAX1)
PTPCAAX1
protein tyrosine phosphatase type IVA, member 1 (EC:3.1.3.48) Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA] increases expression
/ increases reaction
mRNA 19146866
D003513 11156 PTP4A3
PRL-3
PRL-R
PRL3
protein tyrosine phosphatase type IVA, member 3 (EC:3.1.3.48) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 2889 RAPGEF1
C3G
GRF2
Rap guanine nucleotide exchange factor (GEF) 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5919 RARRES2
HP10433
TIG2
retinoic acid receptor responder (tazarotene induced) 2 Cycloheximide results in increased expression of RARRES2 mRNA increases expression
mRNA 19684285
D003513 5919 RARRES2
HP10433
TIG2
retinoic acid receptor responder (tazarotene induced) 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 5933 RBL1
CP107
PRB1
p107
retinoblastoma-like 1 (p107) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Cycloheximide affects the localization of RELA protein affects localization
protein 16637064
D003513 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter] affects binding
/ affects cotreatment
/ increases reaction
protein 16637064
D003513 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter] affects binding
/ increases reaction
protein 16637064
D003513 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] affects binding
/ decreases expression
protein 16637064
D003513 5972 REN
HNFJ2
renin (EC:3.4.23.15) Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein] decreases reaction
/ increases secretion
protein 9203624
D003513 5972 REN
HNFJ2
renin (EC:3.4.23.15) Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein] decreases reaction
/ increases secretion
protein 9203624
D003513 51065 RPS27L
ribosomal protein S27-like [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6283 S100A12
CAAF1
CAGC
CGRP
ENRAGE
MRP-6
MRP6
p6
S100 calcium binding protein A12 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A12 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 6275 S100A4
18A2
42A
CAPL
FSP1
MTS1
P9KA
PEL98
S100 calcium binding protein A4 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 6278 S100A7
PSOR1
S100A7c
S100 calcium binding protein A7 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A7 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) [Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter] affects binding
/ affects cotreatment
/ increases reaction
promoter 16637064
D003513 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA] increases expression
/ increases reaction
mRNA 16637064
D003513 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter] affects binding
/ increases reaction
promoter 16637064
D003513 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]] affects reaction
/ increases expression
/ increases reaction
mRNA 16637064
D003513 90701 SEC11C
SEC11L3
SPC21
SPCS4C
SEC11 homolog C (S. cerevisiae) (EC:3.4.21.89) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA affects cotreatment
/ affects expression
mRNA 19684285
D003513 5272 SERPINB9
CAP-3
CAP3
PI-9
PI9
serpin peptidase inhibitor, clade B (ovalbumin), member 9 Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA] increases expression
/ increases reaction
mRNA 10681578
D003513 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 5270 SERPINE2
GDN
GDNPF
PI-7
PI7
PN-1
PN1
PNI
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 Cycloheximide results in increased expression of SERPINE2 mRNA increases expression
mRNA 19684285
D003513 5270 SERPINE2
GDN
GDNPF
PI-7
PI7
PN-1
PN1
PNI
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 9792 SERTAD2
Sei-2
TRIP-Br2
SERTA domain containing 2 Cycloheximide results in increased expression of SERTAD2 mRNA increases expression
mRNA 19684285
D003513 9792 SERTAD2
Sei-2
TRIP-Br2
SERTA domain containing 2 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 140885 SIRPA
BIT
CD172A
MFR
MYD-1
P84
PTPNS1
SHPS1
SIRP
signal-regulatory protein alpha (EC:3.1.3.48) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 6503 SLA
SLA1
SLAP
Src-like-adaptor Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA] decreases reaction
/ increases expression
mRNA 9020066
D003513 6566 SLC16A1
HHF7
MCT
MCT1
solute carrier family 16 (monocarboxylate transporter), member 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6583 SLC22A4
OCTN1
solute carrier family 22 (organic cation/zwitterion transporter), member 4 Cycloheximide results in increased expression of SLC22A4 mRNA increases expression
mRNA 19684285
D003513 6583 SLC22A4
OCTN1
solute carrier family 22 (organic cation/zwitterion transporter), member 4 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 9481 SLC25A27
UCP4
solute carrier family 25, member 27 Cycloheximide results in increased expression of SLC25A27 mRNA increases expression
mRNA 20385226
D003513 6513 SLC2A1
DYT17
DYT18
DYT9
EIG12
GLUT
GLUT1
GLUT1DS
HTLVR
PED
solute carrier family 2 (facilitated glucose transporter), member 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6528 SLC5A5
NIS
TDH1
solute carrier family 5 (sodium/iodide cotransporter), member 5 Cycloheximide results in increased expression of SLC5A5 mRNA increases expression
mRNA 17164311
D003513 8140 SLC7A5
4F2LC
CD98
D16S469E
E16
LAT1
MPE16
hLAT1
solute carrier family 7 (amino acid transporter light chain, L system), member 5 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 57223 SMEK2
FLFL2
PP4R3B
PSY2
smk1
SMEK homolog 2, suppressor of mek1 (Dictyostelium) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SMEK2 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6606 SMN1
BCD541
GEMIN1
SMA
SMA1
SMA2
SMA3
SMA4
SMA@
SMN
SMNT
T-BCD541
TDRD16A
survival of motor neuron 1, telomeric Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form] decreases reaction
/ increases expression
mRNA 17064354
D003513 22938 SNW1
Bx42
NCOA-62
PRPF45
Prp45
SKIIP
SKIP
SNW domain containing 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 8651 SOCS1
CIS1
CISH1
JAB
SOCS-1
SSI-1
SSI1
TIP3
suppressor of cytokine signaling 1 [hydroxytamoxifen co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA affects cotreatment
/ increases expression
mRNA 16849584
D003513 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA] increases expression
/ increases reaction
mRNA 15330761
D003513 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Cycloheximide results in increased expression of SOD2 mRNA increases expression
mRNA 15330761
D003513 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA] increases expression
/ increases reaction
mRNA 15330761
D003513 6654 SOS1
GF1
GGF1
GINGF
HGF
NS4
son of sevenless homolog 1 (Drosophila) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 6742 SSBP1
Mt-SSB
SOSS-B1
SSBP
mtSSB
single-stranded DNA binding protein 1, mitochondrial Cycloheximide results in increased expression of SSBP1 mRNA increases expression
mRNA 19684285
D003513 6742 SSBP1
Mt-SSB
SOSS-B1
SSBP
mtSSB
single-stranded DNA binding protein 1, mitochondrial [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6489 ST8SIA1
GD3S
SIAT8
SIAT8-A
SIAT8A
ST8SiaI
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 (EC:2.4.99.8) Cycloheximide results in increased expression of ST8SIA1 mRNA increases expression
mRNA 19684285
D003513 6489 ST8SIA1
GD3S
SIAT8
SIAT8-A
SIAT8A
ST8SiaI
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 (EC:2.4.99.8) [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6788 STK3
KRS1
MST2
serine/threonine kinase 3 (EC:2.7.11.1) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 2054 STX2
EPIM
EPM
STX2A
STX2B
STX2C
syntaxin 2 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 6817 SULT1A1
HAST1/HAST2
P-PST
PST
ST1A1
ST1A3
STP
STP1
TSPST1
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (EC:2.8.2.1) Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA] decreases reaction
/ increases expression
mRNA 16308312
D003513 6820 SULT2B1
HSST2
sulfotransferase family, cytosolic, 2B, member 1 (EC:2.8.2.2) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 6827 SUPT4H1
SPT4
SPT4H
SUPT4H
suppressor of Ty 4 homolog 1 (S. cerevisiae) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 11346 SYNPO
synaptopodin Cycloheximide results in increased expression of SYNPO mRNA increases expression
mRNA 19684285
D003513 11346 SYNPO
synaptopodin [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 6867 TACC1
Ga55
transforming, acidic coiled-coil containing protein 1 [Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA affects cotreatment
/ decreases expression
mRNA 15072547
D003513 6867 TACC1
Ga55
transforming, acidic coiled-coil containing protein 1 Cycloheximide results in increased expression of TACC1 mRNA increases expression
mRNA 15072547
D003513 57252 TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein] affects reaction
/ increases phosphorylation
protein 15087236
D003513 57252 TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] affects reaction
/ increases phosphorylation
protein 15087236
D003513 7031 TFF1
BCEI
D21S21
HP1.A
HPS2
pNR-2
pS2
trefoil factor 1 [Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA affects cotreatment
/ increases expression
mRNA 15072547
D003513 7031 TFF1
BCEI
D21S21
HP1.A
HPS2
pNR-2
pS2
trefoil factor 1 Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA] decreases reaction
/ increases expression
mRNA 20875696
D003513 7031 TFF1
BCEI
D21S21
HP1.A
HPS2
pNR-2
pS2
trefoil factor 1 Cycloheximide results in increased expression of TFF1 mRNA increases expression
mRNA 15072547
D003513 7039 TGFA
TFGA
transforming growth factor, alpha Cycloheximide results in increased expression of TGFA mRNA increases expression
mRNA 15228094
D003513 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]] decreases reaction
/ increases expression
protein 9145908
D003513 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] decreases reaction
/ increases expression
protein 9145908
D003513 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA] decreases expression
/ decreases reaction
protein 9145908
D003513 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] decreases reaction
/ increases expression
protein 21303922
D003513 7056 THBD
AHUS6
BDCA3
CD141
THPH12
THRM
TM
thrombomodulin Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 7070 THY1
CD90
Thy-1 cell surface antigen Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 7082 TJP1
ZO-1
tight junction protein 1 Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] decreases reaction
/ increases expression
protein 16087364
D003513 7082 TJP1
ZO-1
tight junction protein 1 Cycloheximide results in decreased expression of TJP1 protein decreases expression
protein 16087364
D003513 51768 TM7SF3
transmembrane 7 superfamily member 3 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA affects cotreatment
/ increases expression
mRNA 19684285
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Cycloheximide inhibits the reaction [IL8 protein affects the secretion of TNF protein] affects secretion
/ decreases reaction
protein 8071060
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA] decreases reaction
/ increases expression
mRNA 22241084
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein] decreases reaction
/ increases expression
protein 12812920
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] decreases reaction
/ increases expression
protein 15701621
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]] decreases reaction
/ increases expression
/ increases reaction
protein 12812920
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] affects cotreatment
/ decreases reaction
/ increases activity
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein] affects cotreatment
/ decreases reaction
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] affects cotreatment
/ increases cleavage
/ increases reaction
protein 12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] affects cotreatment
/ increases cleavage
/ increases reaction
protein 12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein] affects cotreatment
/ increases response to substance
protein 12925536
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA affects cotreatment
/ increases expression
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein affects cotreatment
/ increases secretion
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA] increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA] increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA] increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA] increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA] increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein] increases reaction
/ increases secretion
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor TNF protein results in increased susceptibility to Cycloheximide increases response to substance
protein 16077199
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] decreases reaction
/ increases reaction
/ increases secretion
protein 21146893
D003513 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] affects cotreatment
/ increases expression
/ increases reaction
protein 21146893
D003513 7128 TNFAIP3
A20
OTUD7C
TNFA1P2
tumor necrosis factor, alpha-induced protein 3 (EC:3.4.19.12) [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA affects cotreatment
/ increases expression
mRNA 21146893
D003513 7128 TNFAIP3
A20
OTUD7C
TNFA1P2
tumor necrosis factor, alpha-induced protein 3 (EC:3.4.19.12) Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 21146893
D003513 8797 TNFRSF10A
APO2
CD261
DR4
TRAILR-1
TRAILR1
tumor necrosis factor receptor superfamily, member 10a Cycloheximide inhibits the reaction [docetaxel results in increased expression of TNFRSF10A protein] decreases reaction
/ increases expression
protein 11212279
D003513 8797 TNFRSF10A
APO2
CD261
DR4
TRAILR-1
TRAILR1
tumor necrosis factor receptor superfamily, member 10a Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein] decreases reaction
/ increases expression
protein 11212279
D003513 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Cycloheximide inhibits the reaction [docetaxel results in increased expression of TNFRSF10B protein] decreases reaction
/ increases expression
protein 11212279
D003513 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10B protein] decreases reaction
/ increases expression
protein 11212279
D003513 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Cycloheximide promotes the reaction [celecoxib results in increased expression of TNFRSF10B protein] increases expression
/ increases reaction
protein 15572759
D003513 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Cycloheximide results in increased expression of TNFRSF10B mRNA increases expression
mRNA 15572759
D003513 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide] affects cotreatment
/ increases expression
/ increases localization
/ increases reaction
/ increases response to substance
protein 18222423
D003513 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA affects cotreatment
/ decreases expression
mRNA 19684285
D003513 943 TNFRSF8
CD30
D1S166E
Ki-1
tumor necrosis factor receptor superfamily, member 8 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 18222423
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases cleavage
protein 18222423
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 18222423
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 18222423
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 18222423
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide] affects cotreatment
/ increases expression
/ increases localization
/ increases reaction
/ increases response to substance
protein 18222423
D003513 8600 TNFSF11
CD254
ODF
OPGL
OPTB2
RANKL
TRANCE
hRANKL2
sOdf
tumor necrosis factor (ligand) superfamily, member 11 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 7134 TNNC1
CMD1Z
CMH13
TN-C
TNC
TNNC
troponin C type 1 (slow) Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA] decreases reaction
/ increases expression
mRNA 11007951
D003513 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 15016801
D003513 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 mutant form results in increased susceptibility to Cycloheximide increases response to substance
mutant form 21875941
D003513 9537 TP53I11
PIG11
tumor protein p53 inducible protein 11 Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA] decreases reaction
/ increases expression
mRNA 19333544
D003513 9537 TP53I11
PIG11
tumor protein p53 inducible protein 11 Cycloheximide results in decreased expression of TP53I11 mRNA decreases expression
mRNA 19333544
D003513 8626 TP63
AIS
B(p51A)
B(p51B)
EEC3
KET
LMS
NBP
OFC8
RHS
SHFM4
TP53CP
TP53L
TP73L
p40
p51
p53CP
p63
p73H
p73L
tumor protein p63 Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form] decreases reaction
/ increases expression
protein 20043870
D003513 10426 TUBGCP3
104p
GCP3
Grip104
SPBC98
Spc98
Spc98p
tubulin, gamma complex associated protein 3 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 7296 TXNRD1
GRIM-12
TR
TR1
TRXR1
TXNR
thioredoxin reductase 1 (EC:1.8.1.9) Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA] decreases reaction
/ increases expression
mRNA 15652504
D003513 7296 TXNRD1
GRIM-12
TR
TR1
TRXR1
TXNR
thioredoxin reductase 1 (EC:1.8.1.9) Cycloheximide inhibits the reaction [sulforafan results in increased expression of TXNRD1 mRNA] decreases reaction
/ increases expression
mRNA 12663510
D003513 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA] decreases expression
/ decreases reaction
mRNA 17172411
D003513 7299 TYR
ATN
CMM8
OCA1
OCA1A
OCAIA
SHEP3
tyrosinase (EC:1.14.18.1) Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein] decreases reaction
/ increases activity
protein 14717847
D003513 54658 UGT1A1
BILIQTL1
GNT1
HUG-BR1
UDPGT
UDPGT_1-1
UGT1
UGT1A
UDP glucuronosyltransferase 1 family, polypeptide A1 (EC:2.4.1.17) [Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA affects cotreatment
/ decreases expression
mRNA 15072547
D003513 54658 UGT1A1
BILIQTL1
GNT1
HUG-BR1
UDPGT
UDPGT_1-1
UGT1
UGT1A
UDP glucuronosyltransferase 1 family, polypeptide A1 (EC:2.4.1.17) Cycloheximide results in decreased expression of UGT1A1 mRNA decreases expression
mRNA 15072547
D003513 7366 UGT2B15
HLUG4
UDPGT_2B8
UDPGT2B15
UDPGTH3
UGT2B8
UDP glucuronosyltransferase 2 family, polypeptide B15 (EC:2.4.1.17) Cycloheximide results in increased expression of UGT2B15 mRNA increases expression
mRNA 16690804
D003513 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA] decreases reaction
/ increases expression
mRNA 11641398
D003513 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Cycloheximide results in increased expression of VEGFA mRNA increases expression
mRNA 11641398
D003513 7436 VLDLR
CARMQ1
CHRMQ1
VLDLRCH
very low density lipoprotein receptor Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 7447 VSNL1
HLP3
HPCAL3
HUVISL1
VILIP
VILIP-1
visinin-like 1 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA] decreases expression
/ decreases reaction
mRNA 11007951
D003513 10413 YAP1
YAP
YAP2
YAP65
YKI
Yes-associated protein 1 [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA affects cotreatment
/ increases expression
mRNA 19684285

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (80)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#612069 Amyotrophic lateral sclerosis 10, with or without frontotemporal dementia; als10 Q13148
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#300068 Androgen insensitivity syndrome; ais P10275
#312300 Androgen insensitivity, partial; pais P10275
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
%606641 Body mass index; bmi P37231
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#609338 Carotid intimal medial thickness 1 P37231
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#114500 Colorectal cancer; crc P84022
#162800 Cyclic neutropenia P08246
#127750 Dementia, lewy body; dlb P37840
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#614557 Ehlers-danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; edskmh Q9NWM8
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 O75874
P04626
P37231
#610140 Heart-hand syndrome, slovenian type P02545
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#143100 Huntington disease; hd P42858
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#603932 Intervertebral disc disease; idd P14780
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#604367 Lipodystrophy, familial partial, type 3; fpld3 P37231
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#612371 Major affective disorder 7; mafd7 P17861
#608516 Major depressive disorder; mdd P08172
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#257220 Niemann-pick disease, type c1; npc1 O15118
#601665 Obesity P32245
P37231
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#168601 Parkinson disease 1, autosomal dominant; park1 P37840
#605543 Parkinson disease 4, autosomal dominant; park4 P37840
#168600 Parkinson disease, late-onset; pd P37840
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#313200 Spinal and bulbar muscular atrophy, x-linked 1; smax1 P10275
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#190300 Tremor, hereditary essential, 1; etm1 P35462
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (80)

KEGG disease name UniProt
H00136 Niemann-Pick disease type C (NPC) O15118 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
P37231 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
P37231 (related)
H00033 Adrenal carcinoma P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00024 Prostate cancer P10275 (related)
H00062 Spinal and bulbar muscular atrophy (SBMA) P10275 (related)
H00608 46,XY disorders of sex development (Disorders in androgen synthesis or action) P10275 (related)
H00609 46,XY disorders of sex development (Other) P10275 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00409 Type II diabetes mellitus P37231 (related)
H00057 Parkinson's disease (PD) P37840 (related)
H00066 Lewy body dementia (LBD) P37840 (related)
H00059 Huntington's disease (HD) P42858 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00058 Amyotrophic lateral sclerosis (ALS) Q13148 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)

Diseases related to CTD interactions

16 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000647 D003513 Amnesia marker/mechanism
2273650
2547386
7617693
12650838
D019970 D003513 Cocaine-Related Disorders therapeutic
16777145
D056486 D003513 Drug-Induced Liver Injury marker/mechanism
19395591
22331495
D005909 D003513 Glioblastoma marker/mechanism
7841041
7861226
D006949 D003513 Hyperlipidemias therapeutic
69995
D007174 D003513 Impulse Control Disorders therapeutic
6458665
D007249 D003513 Inflammation marker/mechanism
21146893
D007859 D003513 Learning Disorders marker/mechanism
9147253
16343452
D008223 D003513 Lymphoma therapeutic
19412536
D008569 D003513 Memory Disorders marker/mechanism
561405
6817363
D009135 D003513 Muscular Diseases therapeutic
6654876
D009336 D003513 Necrosis marker/mechanism
therapeutic
171611
17617453
19041363
D009410 D003513 Nerve Degeneration therapeutic
9710261
23335626
D009422 D003513 Nervous System Diseases therapeutic
11756511
D011041 D003513 Poisoning therapeutic
22155090
D013226 D003513 Status Epilepticus therapeutic
7925839